Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
This is from Inaco on other board , please cane someone post next link to conference?
From other side
a week away from the next conference
lets hope any update gets an RNS
have we heard about the proposed Doublet in renal ? that was about 10 weeks ago from interims
Modi-1 to be assessed in renal cell carcinoma in combination with double CPI therapy in the ModiFY study pending protocol amendment by the MHRA
Thanks EE. Forgive me
I have had a very busy morning. Only scanned it sorry
Nottingham university hiring 3 researchers for glycocell engineering
3 industrial partners ? Who could they be , think Cath Merry mentioned one . ? Think about the government contracts mentioned in a slide from
Sarah Danson . Investigator for both scope trial and Moditope. The ref to the 2 Australian melanoma experts and achievements of eradication of Glibastoma by conducting a trials on himself. Wonder what that could have been
https://m.youtube.com/watch?v=oae33WdkLx8&list=PLF1-XapOV1fePHKA-Yd3PMIHwlr82NY9V&index=3&pp=iAQB
I would encourage you all to watch
“The GlycoCell Engineering Biology Mission Hub, the GlycoWeb BBSRC sLOLA, the anti-glycan antibodies of Scancell Ltd and other glyco-connected work at University of Nottingham put us very much at the centre of of the glyco-revolution in life science, bio-medicines and diagnostics. Watch this space “
https://jobs.nottingham.ac.uk/vacancy.aspx?ref=MED2006
Johnathan van tam ( Nottingham university)adviser to Moderna
We know research collaboration exists between Biontech and Scancell to
We know Genmab are working with Genmab
All very interesting innovations
Good luck to one and all
LinkedIn post from
Cathy Merry of Nottingham university
Professor of Stem Cell Glycobiology, Faculty of Medicine & Health Science
People - The University of Nottingham
This is fantastic! Really excited by the plans built up by John Heap and the team. The GlycoCell Engineering Biology Mission Hub, the GlycoWeb BBSRC sLOLA, the anti-glycan antibodies of Scancell Ltd and other glyco-connected work at University of Nottingham put us very much at the centre of of the glyco-revolution in life science, bio-medicines and diagnostics. Watch this space..
The University of Nottingham will lead a national hub that will develop vaccines, diagnostics and therapeutics, benefiting millions of people worldwide, thanks to funding from UK Research and Innovation (UKRI).
The GlycoCell Engineering Biology Mission Hub will receive £12.3 million in funding as part of an overall investment of £100m from UKRI’s Technology Missions Fund and UKRI and BBSRC’s core budgets.
https://www.nottingham.ac.uk/news/glycocell-engineering-biology-mission-hub
Link to the Todays Times article behind a paywall
https://www.thetimes.co.uk/article/exodus-from-aim-leaves-chorus-of-questions-in-its-wake-93d0mrvjx
extracts from article that are relevant :
The problem of weak valuations is behind C4X’s decision to take the company private at a meeting on Monday. Clive Dix, 69, its chief executive and the former deputy chairman of the Covid-19 vaccine taskforce, said: “We believe we should be valued at least five times, if not ten times what we are and therefore raising money at ten times the value would be much simpler. I don’t think it’s to do with the quality of the companies and the science. I just think that the environment, it doesn’t work. There’s no liquidity.”
Redx, a cancer drug developer, are down by more than 90 per cent from their 2015 listing, despite establishing four “major” partnering deals over the past five years.
Gervais Williams, head of equities at Premier Miton Investors, a long-term proponent of smaller listed companies, said it was not surprising that some businesses were leaving Aim. “The UK is cheap, but small caps are disgustingly, absurdly cheap,” he said. “A lot of companies feel that they’re not getting value for all of the extra cost and hassle of meeting the reporting requirements of being on Aim.”
Nevertheless, he reckons a broad rally in UK-listed shares is coming, with the FTSE 100 index flirting with a record high. This, he believes, will result in a “positive virtuous spiral” that will boost smaller listed companies. “I’m more bullish now than I’ve been for 30 years.”
Xodus from Aim leaves chorus of questions in its wake
https://www.thetimes.co.uk/article/exodus-from-aim-leaves-chorus-of-questions-in-its-wake-93d0mrvjx
The problem of weak valuations is behind C4X’s decision to take the company private at a meeting on Monday. Clive Dix, 69, its chief executive and the former deputy chairman of the Covid-19 vaccine taskforce, said: “We believe we should be valued at least five times, if not ten times what we are and therefore raising money at ten times the value would be much simpler. I don’t think it’s to do with the quality of the companies and the science. I just think that the environment, it doesn’t work. There’s no liquidity.”
Redx, a cancer drug developer, are down by more than 90 per cent from their 2015 listing, despite establishing four “major” partnering deals over the past five years.
Gervais Williams, head of equities at Premier Miton Investors, a long-term proponent of smaller listed companies, said it was not surprising that some businesses were leaving Aim. “The UK is cheap, but small caps are disgustingly, absurdly cheap,” he said. “A lot of companies feel that they’re not getting value for all of the extra cost and hassle of meeting the reporting requirements of being on Aim.”
Nevertheless, he reckons a broad rally in UK-listed shares is coming, with the FTSE 100 index flirting with a record high. This, he believes, will result in a “positive virtuous spiral” that will boost smaller listed companies. “I’m more bullish now than I’ve been for 30 years.”
https://www.thetimes.co.uk/article/exodus-from-aim-leaves-chorus-of-questions-in-its-wake-93d0mrvjx
The problem of weak valuations is behind C4X’s decision to take the company private at a meeting on Monday. Clive Dix, 69, its chief executive and the former deputy chairman of the Covid-19 vaccine taskforce, said: “We believe we should be valued at least five times, if not ten times what we are and therefore raising money at ten times the value would be much simpler. I don’t think it’s to do with the quality of the companies and the science. I just think that the environment, it doesn’t work. There’s no liquidity.”
Redx, a cancer drug developer, are down by more than 90 per cent from their 2015 listing, despite establishing four “major” partnering deals over the past five years.
Gervais Williams, head of equities at Premier Miton Investors, a long-term proponent of smaller listed companies, said it was not surprising that some businesses were leaving Aim. “The UK is cheap, but small caps are disgustingly, absurdly cheap,” he said. “A lot of companies feel that they’re not getting value for all of the extra cost and hassle of meeting the reporting requirements of being on Aim.”
Nevertheless, he reckons a broad rally in UK-listed shares is coming, with the FTSE 100 index flirting with a record high. This, he believes, will result in a “positive virtuous spiral
I agree C11 in 2020 was indeed interesting especially Redmile were also early investors of BioNTech let’s hope magic rubs off in all directions for patients and share price
The collaboration agreement with BioNTech 2019
Scancell to collaborate with BioNTech
Scancell to collaborate with BioNTech to investigate T cell receptor based therapeutics for the treatment of cancer
Agreement expands potential therapeutic utility of Moditope® to adoptive T cell therapy
Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has entered into a research collaboration with BioNTech for the potential development of innovative, T cell receptor based therapeutics for the treatment of cancer. This research collaboration combines Scancell’s Moditope® immunotherapy platform and BioNTech’s platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.
Moditope® represents a completely new class of potent and selective immunotherapy agents which could have a profound effect on the way that cancer immunotherapies are developed. It acts by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes which overcome self-tolerance and destroy tumour cells. The technology overcomes the immune suppression induced by tumours themselves without the need for checkpoint blockade inhibitors, thereby allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.
Under the terms of the agreement, Scancell and BioNTech will enter into an initial research collaboration to discover and characterise T cell receptors specific for citrullinated epitopes from vimentin and enolase. These epitopes form the basis of Scancell’s first Moditope® development candidate, Modi-1. Upon completion of these studies, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Modi-1 epitopes.
A reminder of the research agreement with BioNTech
https://www.scancell.co.uk/scancell-to-collaborate-with-biontech
TF
Thanks for your post .. I found this was posted by Scancell in their LinkedIn page . And has had 64 likes
I find it odd again mentioning Biontech ?
I also posted A video of prof Sarah Danson ( an author of the abstract ) from the focus melanoma conference . Sponsors by Scancell . Ther was a whole slide seditious The uk government investment / partnership with Biontech and Moderna ?
Wonder where the research collaboration with Scancell and BioNTech agreed in 2019 !
Seems odd BioNTech mentioned in Rns post LinkedIn page and presentation at Mellanoma conference .
I have cut and paste from Scancell LinkedIn page
ICYMI, Scancell Ltd CEO Lindy Durrant presented data at American Association for Cancer Research on its open-label Phase 2 SCOPE trial investigating its cancer vaccine, SCIB1 in advanced melanoma, as part of the #AACR ‘Cancer Vaccines: Ready for Prime Time?’ clinical trials symposium.
The session covered progress from a number of other innovative clinical stage cancer vaccines including follow up data from the BioNTech mRNA vaccine, which reported T cells could still be detected at the three-year follow-up point. This is highly encouraging for the cancer vaccine space, particularly as SCIB1 has demonstrated an 85% response rate among 13 first-line advanced melanoma patients.
🔎 Learn more about SCOPE: https://lnkd.in/eivcrTxX
#cancervaccine #melanoma #AACR24 #immunooncology #immunotherapy
#ICYMI, Scancell Ltd CEO Lindy Durrant presented data at American Association for Cancer Research on its open-label Phase 2 SCOPE trial investigating its cancer vaccine, SCIB1 in advanced melanoma, as part of the #AACR ‘Cancer Vaccines: Ready for Prime Time?’ clinical trials symposium.
The session covered progress from a number of other innovative clinical stage cancer vaccines including follow up data from the BioNTech mRNA vaccine, which reported T cells could still be detected at the three-year follow-up point. This is highly encouraging for the cancer vaccine space, particularly as SCIB1 has demonstrated an 85% response rate among 13 first-line advanced melanoma patients.
🔎 Learn more about SCOPE: https://lnkd.in/eivcrTxX
#cancervaccine #melanoma #AACR24 #immunooncology #immunotherapy
Https://m.youtube.com/watch?v=oae33WdkLx8&list=PLF1-XapOV1fePHKA-Yd3PMIHwlr82NY9V&index=3&pp=iAQB
Prof Sarah Danson was author of abstract
This year's Melanoma Patient Conference session videos are now LIVE! 📽
You can access all of this year's sessions here: https://buff.ly/3xAae3u
Once again thank you to all of those who made this year's event such a great success! We look forward to welcoming you again next year.
#melanoma #melanomapatientconference #patientconference #mpc2024
Oncology is the single largest market in the global biopharma industry, worth over $200B. Here's a look at the top 15 drugs in the space, and some insights behind the numbers:
1. Several top sellers are facing LOEs soon: Pfizer's Ibrance faces competition in 2027, while Merck's Keytruda and BMS's Opdivo face expirations in 2028.
2. 4 drugs gained over $1B each in addition sales compared to 2022:
Keytruda (up $4.1B) Darzalex (up $1.8B) Imfinzi (up $1.5B) and Verzenio (up $1.4B).
The biggest decliner was BMS's Revlimid, which saw sales drop by almost $4B from 2022.
3. It is notable just how much these drugs depend on the US market for revenue - for several of the top drugs (e.g., Darzalex, Opdivo, and Ibrance), US sales accounted for well over 50% of total revenue.
The next few years have a lot in store - major LOEs, new modalities like ADCs, and more favorable capital markets - all of which will continue to make oncology one of the most dynamic parts of biopharma.
Infographic showing the 15 biggest oncology drugs by revenue in 2023, along with logos of the companies that made each drug
I agree Bobbust that’s some cash burn 🔥
Yes EE and they issues a press release prior ( see below ) however is didn't make it on the list for a recent article covering cancer vaccines see below
Inoculating Hope: The Landscape of Cancer Vaccination
Apr 08, 2024 | Reading Time: 2 minutes
https://www.delveinsight.com/blog/cancer-vaccines-landscape
Apr 08, 2024 | Reading Time: 2 minutes
Cancer vaccines represent a novel approach in cancer treatment, leveraging the body’s immune system to identify and eradicate cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate an immune response against specific proteins found on cancer cells, potentially preventing cancer recurrence and impeding tumor progression. Recent strides in personalized medicine have facilitated the development of tailored cancer vaccines, which target individual tumor characteristics, thereby enhancing efficacy while minimizing adverse effects. Despite some setbacks in the past, ongoing research in immunotherapy, including cancer vaccines, remains a focal point of interest at this year’s AACR conference.
Here is our entry on the list
Scancell SCIB1 Advanced unresectable melanoma SCOPE
(NCT04079166) II CT024 A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial
Press release ahead of presentation 7th of April 2024
New Phase 1 Data from Memorial Sloan Kettering Cancer Center Shows an Investigational Cancer Vaccine May Elicit Lasting Immune Response in Patients with Pancreatic Cancer
https://www.mskcc.org/news-releases/new-phase-1-data-from-mskcc-shows-investigational-cancer-vaccine-may-elicit-lasting-immune-response-in-patients-with-pancreatic
This speaker was after Lindy Durrant
CT025 Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer. Vinod P. Balachandran, New York, NY
https://health.usnews.com/doctors/vinod-balachandran-118798
So many meetings rooms . Considering a lot will want to listen to the 15 minutes in the PRIME spot at the worlds most important conference
Ballroom Theater Classroom Banquet Reception
20 A 1,330 860 580 1,880
20 A–B 2,214 1,352 980 2,865
20 A–C 3,052 1,856 1,380 3,857
20 B–C 1,330 896 600 1,985
20 B–D 3,034 1,912 1,380 3,943
20 C–D 2,132 1,352 980 2,865
20 D 1,400 848 680 1,960
20 A–D 4,800 2,904 1,960 5,820
Yes sorry typo it’s ballroom 20 ! Yes it is huge , not just the room . It’s the news on the trial and explanation of how much Avidimab will impact and improve patients lives
A 15 minute captive audience on the hot subject of . Cancer vaccines being ready for PRIME TIME !
I found this interesting . the presentation in Ballroom 50 a large room with lots of seating ? :
Presentation and Session Format. Speakers in regular Minisymposia and Clinical Trials Minisymposia have 10 minutes to present their talks and five minutes to answer questions.
Advance Preparation with Session Chairpersons.
[Note: These instructions and deadlines apply to presenters in regular Minisymposia. Presenters in Clinical Trials Minisymposia have a later deadline for slide upload and should refer to their e-mail notification for instructions.]
so updated slides and 5 minutes answering questions at roughly midnight ? would love to know what questions will be asked ? especially the answers ?
Looking forward to 7 am tomorrow ?